The Road Ahead for the Dengvaxia Market: Key Growth Trends and Opportunities to Watch
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What CAGR is Anticipated for the Dengvaxia Market During the Forecast Period, and Why?
In the past few years, the market size for Dengvaxia has experienced a significant increase. Its growth is projected to rise from $181.23 million in 2024 to $213.36 million in 2025, with a compound annual growth rate (CAGR) of 17.7%. The expansion seen in the historical period could be linked to efforts made by the government in health, heightened public awareness about health, the importance of preventive steps, an increase in dengue cases related to travel, and enhancements in healthcare infrastructure.
The market size for dengvaxia is anticipated to witness a swift expansion in the upcoming years. This market is set to reach $404.70 million by 2029, growing at a compound annual growth rate (CAGR) of 17.4%. The projected growth during this period is credited to increasing occurrences of dengue flare-ups, augmented government financial backing, partnerships between public and private entities, escalating public consciousness about dengue prevention, and improved healthcare structures. The period is expected to showcase significant trends such as progression in vaccination technology, relentless research and development, pioneering vaccine administration methods, creation of new compounds, and enhanced practices for vaccine storage and distribution.
What Strategic Factors Are Influencing the Accelerated Growth of the Dengvaxia Market?
The increasing occurrence of dengue is believed to fuel the expansion of the dengvaxia market in the future. Dengue, a viral infection spread by the Aedes mosquito results in flu-like symptoms, intense pain, and severe complications such as dengue hemorrhagic fever or dengue shock syndrome if not treated. Factors like climate change, urbanization, the growth of mosquito breeding areas, and increased travel are causing a rise in dengue cases which, in turn, is growing the demand for prevention and treatment. Dengvaxia, a highly effective vaccine, prompts the immune system to protect against the dengue virus decreasing the infection risk and serious consequences, while improving public health results in regions with endemic dengue. As an example, the Americas reported over 9.7 million dengue cases in 2024, says the Centers for Disease Control and Prevention (CDC) in June of the same year, that was two-fold the 4.6 million cases reported in 2023. Moreover, amidst 1,498 cases, a public health emergency was declared in Puerto Rico and 745 cases surfaced among U.S. travelers. As such, the dengvaxia market is expanding due to the escalating occurrence of dengue.
Request Your Free Dengvaxia Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20035&type=smp
Which Companies Are Poised to Shape the Future of the Dengvaxia Market?
Major companies operating in the dengvaxia market include Sanofi Pasteur Inc.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/dengvaxia-global-market-report
Which Industry Segments Are Leading the Development and Expansion of the Dengvaxia Market?
The dengvaxia market covered in this report is segmented –
1) By Type: Dengvaxia, Other Types
2) By Distribution Channel: Hospitals, Clinics, Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use
What Regions Are Contributing Significantly to the Growth of the Dengvaxia Market?
Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Is the Scope and Reach of the Dengvaxia Market Defined?
Dengvaxia is a recombinant vaccine developed to protect against dengue fever, a viral illness transmitted by Aedes mosquitoes, by stimulating the immune system to produce a targeted response that helps prevent infection and severe complications, contributing to public health efforts in regions where dengue is endemic.
Browse Through More Similar Reports By The Business Research Company:
Yellow Fever Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/yellow-fever-vaccine-global-market-report
Influenza A Virus Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report
Typhoid Vi Polysaccharide Vaccine Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
